Anteris Technologies Global Corp. — Capital/Financing Update 2022

May 30, 2022

ASX ANNOUNCEMENT

31 May 2022

SUCCESSFUL COMPLETION OF SECOND FIRST-IN-HUMAN STUDY

Brisbane, Australia and Minneapolis, USA, Anteris Technologies Ltd (ASX: AVR, Anteris or the Company) reports eight more patients were successfully treated last week, as part of the ongoing first-in-human DurAVR[™] THV study conducted at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.

Anteris’ Chief Medical Officer, Dr Chris Meduri, has overseen the study, including the initial five aortic stenosis patients implanted with DurAVR™ THV last November at the Tbilisi Heart and Vascular Clinic.

Australian Physician Dr Karl Poon was in attendance and became the first Australian doctor to implant a patient with the DurAVR[™] THV.

Data from the latest cohort will be reviewed at the 30-day follow-up which is the key inflexion point for indicating ongoing valve performance. All patients enrolled in the study have done exceptionally well.

“We are thrilled with the ongoing progress and the veracity of the results so far. The whole team including the treating physicians are excited by the results so far. The Company continues to progress its clinical program and I look forward to updating the market in the near future” Anteris CEO, Wayne Paterson, said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris’ DurAVR[™] 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[™] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service

==> picture [95 x 51] intentionally omitted <==

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Hannah Howlett WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 4 5064 8064 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech LinkedIn: https://www.linkedin.com/company/anteristech

==> picture [95 x 52] intentionally omitted <==